TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York City, with both in-person and virtual options available. Bryan Kobel, CEO of TC BioPharm, will present an overview of the company's business during the conference. The event will feature over 550 corporate presentations and panels, providing investors with opportunities to learn about various companies and schedule individual meetings with management teams.
TC BioPharm (NASDAQ: TCBP), un'azienda biotecnologica in fase clinica che sviluppa terapie con cellule T gamma-delta allogeniche, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York, con opzioni sia in presenza che virtuali disponibili. Bryan Kobel, amministratore delegato di TC BioPharm, presenterà una panoramica delle attività dell'azienda durante la conferenza. L'evento presenterà oltre 550 presentazioni aziendali e panel, offrendo agli investitori opportunità di conoscere diverse aziende e programmare incontri individuali con i team di gestione.
TC BioPharm (NASDAQ: TCBP), una empresa de biotecnología en etapa clínica que desarrolla terapias con células T gamma-delta alogénicas, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento tendrá lugar del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York, con opciones disponibles tanto presenciales como virtuales. Bryan Kobel, director ejecutivo de TC BioPharm, presentará una visión general del negocio de la empresa durante la conferencia. El evento contará con más de 550 presentaciones corporativas y paneles, proporcionando a los inversores oportunidades para aprender sobre varias empresas y programar reuniones individuales con los equipos de gestión.
TC BioPharm (NASDAQ: TCBP), 동종 감마-델타 T세포 치료제를 개발하는 임상 단계의 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕시에서 개최되며 대면 및 가상 옵션이 제공됩니다. TC BioPharm의 CEO인 Bryan Kobel이 회의 중 회사 사업 개요를 발표할 것입니다. 이 행사에는 550개 이상의 기업 발표 및 패널이 포함되어 있으며, 투자자에게 다양한 기업에 대해 배우고 경영진과 개별 회의를 일정을 잡을 수 있는 기회를 제공합니다.
TC BioPharm (NASDAQ: TCBP), une société de biotechnologie en phase clinique développant des thérapies par cellules T gamma-delta allogéniques, a annoncé sa participation à la 26ème Conférence Annuelle Globale sur les Investissements H.C. Wainwright. L'événement aura lieu du 9 au 11 septembre 2024 à New York, avec des options disponibles à la fois en personne et virtuellement. Bryan Kobel, PDG de TC BioPharm, présentera un aperçu des activités de l'entreprise lors de la conférence. L'événement comprendra plus de 550 présentations d'entreprises et panneaux, offrant aux investisseurs des opportunités de découvrir différentes entreprises et d'organiser des réunions individuelles avec les équipes de direction.
TC BioPharm (NASDAQ: TCBP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das allogene Gamma-Delta-T-Zelltherapien entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York City statt, mit Optionen sowohl für persönliche als auch für virtuelle Teilnahme. Bryan Kobel, CEO von TC BioPharm, wird während der Konferenz einen Überblick über das Unternehmen geben. Die Veranstaltung wird über 550 Unternehmenspräsentationen und Panels umfassen und bietet Investoren die Möglichkeit, verschiedene Unternehmen kennenzulernen und individuelle Meetings mit den Führungsteams zu planen.
- Participation in a major investment conference, potentially increasing investor visibility
- CEO presenting company overview, indicating active engagement with investors
- None.
The in-person venue for the event is the Lotte New York Palace Hotel in
Bryan Kobel, CEO of TC BioPharm, will provide an overview of the Company's business during the presentation. More than 550 corporate presentations & panels are available during the event. For more information or if you are interested in scheduling an individual meeting with management, please contact the company directly at ir@tcbiopharm.com.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302239053.html
SOURCE TC BioPharm
FAQ
When and where is TC BioPharm (TCBP) participating in the H.C. Wainwright Global Investment Conference?
Who will be presenting for TC BioPharm (TCBP) at the H.C. Wainwright conference?
How can investors schedule a meeting with TC BioPharm (TCBP) management during the conference?
What type of therapies is TC BioPharm (TCBP) developing?
